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Abstract
Capsaicin, a pungent alkaloid of chili pepper (Capsicum annuum) is responsible for the 
“hot and spicy” taste of chili. Also, Capsaicin is a pharmaceutical agent with broad thera-
peutic applications in controlling different diseases like diabetes, obesity, cancer, pain, 
and other inflammatory diseases. Capsaicin therapeutic effect is dependent on various 
factors like the concentration of capsaicin, delivery to different cell types, route of admin-
istration, and their metabolism. Improvement in the delivery of capsaicin will increase its 
therapeutic efficacy. Recent advancement in various technologies had provided numer-
ous strategies to deliver capsaicin. This chapter outlines different strategies for using 
multiple new materials, formulations for the capsaicin delivery and improve their thera-
peutic efficacy as well their advantages and disadvantages.
Keywords: capsaicin, drug delivery, micro and nanotechnology tools, pharmaceutical 
formulations
1. Introduction
Capsaicin (trans-8-methyl-N-vanillyl-6-nonenamide), one of the active ingredient of chili pep-
pers, possess pungent flavor, was first isolated in 1816 in partially purified crystalline form by 
Bucholz and in a pure crystalline form in 1876 by Thresh [1], who named it capsaicin. Nelson 
partially solved the structure of capsaicin in 1919 [2], and the compound has initially been 
synthesized in 1930 by Späth and Darling [3]. Capsaicin is one of the member of capsaicinoids 
family and other members of capsaicinoids are shown in Figure 1. Capsaicin biosynthesis in 
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Figure 2. Pathological mechanisms involved when capsaicin modulates TRPV1 channel.
plants is defined by two pathways: phenylpropanoid, which determines phenolic structure; 
and fatty acid metabolism, which determines the molecule’s fatty acids [3]. Capsaicin concen-
tration increases gradually during fruit development reaching maximum levels at 40–50 days. 
Level of capsaicin increases by the increase in the activity of the enzymes phenylalanine 
ammonia-lyase (PAL), cinnamic acid-4-hydroxylase (C4H) and capsaicin synthase enzyme 
(CS), all involved in capsaicin biosynthesis [4]. Capsaicin is an odorless fat-soluble compound 
which is used to spice up cuisines, especially in Mexico and South America. Europeans intro-
duced chili peppers to Asia and Africa, and they are now an essential ingredient of cuisines 
in Ethiopia, India, China, Sri Lanka, Thailand, Korea and Malaysia [5]. The Scoville heat units 
are used to measure the ‘hotness’ of chili peppers, which represents the number dilution 
required with water for it to lose its heat. Capsaicin scores about 16,000,000 units. The “heat 
Figure 1. Three-dimensional structure representation of capsaicin and their derivatives present in chili pepper, were 
retrieved from PubChem database.
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sensation” of capsaicin arises due to the binding of capsaicin to transient receptor potential 
vanilloid subfamily member 1 (TRPV1) ion-channel receptors. Capsaicin also is known as 
a modulator of TRPV1 [6]. A unique feature called as defunctionalization is responsible for 
capsaicin to use as therapeutic use. Capsaicin is proven to be beneficial in many physiologi-
cal systems and can be used to treat diseases like pain, cancer, diabetes, obesity, infectious 
diseases, and inflammatory diseases (as shown in Figure 2). Many pharmacological and pain 
research studies have shown the multiple effects of capsaicin in a variety of physiological 
systems (cardiovascular, respiratory, and urinary) [7].
2. Mechanism of action
The device of action of capsaicin has been studied widely from the past decades. Nearly 
20 years ago, it was demonstrated that capsaicin releases substance P from afferent nocicep-
tive neurons. Capsaicin activates afferent nociceptive neurons and evokes sensations ranging 
from hotness to burning. The depletion of substance P mediates the analgesic properties of 
capsaicin that leads to the desensitization of small afferent sensory neurons [8]. Capsaicin 
binds to a specific nerve membrane receptor, the Transient Receptor Potential V1 receptor 
(previously known as vanilloid receptor, VR1 or TRPV1) encoded by gene TRPV1 gene. 
Capsaicin plays an essential role in the transmembrane signaling receptor. The TRPV1 recep-
tors also respond to temperature, acidosis, painful stimuli, and osmolarity. TRPV1 has a cen-
tral role in thermal nociception and inflammatory hyperalgesia [9]. The human and rodent 
TRPV1 receptor which consists of 838 amino acids (molecular weight of 95 kDa) was identi-
fied and cloned in rats in 1997 by Caterina [10]. The distribution of TRPV1 is there in other tis-
sues such as the brain [11], bladder [12], kidney, and bowel [13]. Endovanilloids may regulate 
and activate the channels. TRPV1 is expressed not only on cellular membranes but also on 
Figure 3. A represents the three dimensional structure of TRPV1 (adopted from PDB ID 3J5Q) and B represents TRPV1-
capsaicin complex especially S3 and S4 domain interacting residues adopted from [17].
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the endoplasmic reticulum [14]. Endoplasmic reticulum expression of regulates intracellular 
calcium levels, reverses the phosphorylation by involvement of kinases and phosphatases, 
role in formation of heteromers and regulate gene expression as well. Recently structural 
biology researchers, investigate the binding pose of capsaicin bound to TRPV1 channel, and 
it was resolved using cryo-EM. This study revealed that Capsaicin stabilizes TRPV1’s open 
state by ‘pull-and-contact’ interactions between the vanillyl group and the S4-S5 linker. The 
 interacting residues involved in capsaicin-TRPV1 channels are TYR 511, M547, and T550(as 
shown in Figure 3) [15]. Once, the agonists like capsaicin activate TRPV1 channels, many 
intracellular proteins containing Ankyrin repeats (AR) initiate signaling pathways, NFkB 
pathways, Apoptosis, degrade ubiquitin ligase, p38 -MAPK signaling pathway, controlling 
calcium ion concentration, regulating ATP metabolism, PIP2 hydrolysis, inhibiting CDk2, 
CDK4, and CDK6, and controlling cell cycle progression. Hence, Capsaicin-treated cells were 
proven to be anticancer, antidiabetic, and anti-inflammatory [16].
3. Metabolism of capsaicin
Metabolism of capsaicin is very rapid in the human stratum corneum, and it is dependent on 
the solubility of capsaicin in non-polar viscous solvents [18]. Oral administration of capsaicin 
is rapidly metabolized in liver, kidney, intestine, and in blood peak concentration is observed 
in 1 h [19]. In human studies, oral administration of 5 g of capsaicin and capsaicinoids to 
healthy volunteers had resulted in significant reduction in plasma glucose levels and also, 
increase in plasma insulin levels (Observed pharmacokinetics in this study are C(max), 
T(max), AUC(0-t), T1/2 are 2.47 ± 0.13 ng/ml, 47.08 ± 1.99 min, 103.6 ± 11.3 ng × min/ml, and 
24.87 ± 4.97 min, respectively.) [20]. Topical administration of capsaicin [(640 μg/cm2) like 
capsaicin patch, also called as NGX-4010] to different diseased patients, had resulted in quan-
tifiable amounts of capsaicin. The amount of capsaicin detected in plasma is 31% for posther-
petic neuralgia (PHN), 7% for painful human immunodeficiency virus-associated neuropathy 
(HIV-AN), and 3% for painful diabetic neuropathy (PDN) [21]. Intravenous administration of 
capsaicin leads to the rapid entry of capsaicin in the central nervous system, and their metabo-
lism is low when compared to liver and kidney [22]. Bioavailability and half-life of capsaicin 
are low and is independent of the route of administration. This leads to investigate in the 
areas to design and develop new strategies to improve drug-delivery of capsaicin, to enhance 
their bioavailability and half-life.
4. General strategies for capsaicin delivery and their clinical 
challenges
To date, capsaicin formulations on the market include Capzasin-HP (Topical Analgesic Cream), 
Qutenza patches, LEADER CAPSAICIN (cream). The current administration of  commercial 
capsaicin comprises topical delivery. Challenges in the clinical application of capsaicin are its 
short half-life, low bioavailability, produces burning sensation and side effects are dependent 
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on the concentration of capsaicin, skin irritation, burning and others. Alternative approaches 
have been extensively explored, to improve the delivery of capsaicin, including oral, gastro-
intestinal, intraperitoneal, subcutaneous, topical, and ocular. Emerging micro and nanotech-
nologies have attracted and lead to a general idea to encapsulate capsaicin to various carriers 
like lipid-based carriers (liposomes, microemulsion, solid-lipid nanoparticle), polymeric car-
riers (micelle, dendrimer, and polymersome), Inorganic carriers (metal nanoparticles, carbon 
spheres). The primary objective of chosen carriers is: (1) improve bioavailability; (2) enhance 
delivery to different cell types; (3) improve pharmacokinetics; (4) improve half-life of capsaicin.
5. Micro and nanotechnology tools to deliver capsaicin
Topical administration is the only method used in clinical use and as well to deliver capsaicin 
for pain treatment. Certain drawbacks observed by patients are, the short half-life of capsa-
icin, bioavailability is low, burning sensation of capsaicin had resulted in patient discom-
fort. In this study, we report different strategies proven to be successful at research level to 
improve the bioavailability, increase the half-life, reduce irritation, different routes of admin-
istration, use of micro and nanotechnology tools to improve the drug delivery and overcome 
the drawbacks of capsaicin treatment. Micro and nanotechnology tools were classified into 
three categories: lipid-based carriers, polymeric carriers, and inorganic nanocarriers.
5.1. Lipid based carriers
Liposome, microemulsions and solid lipid nanoparticles are chosen to be considered in the 
category of lipid-based carriers (as shown in Figure 4). Briefly, Liposomes (20 nm to several 
microns) can be used to encapsulate hydrophilic and hydrophobic compounds. Lipid con-
stituent, surface charge, the physical state of the phospholipid bilayer plays a vital role in the 
enhancement of therapeutic efficacy of encapsulated pharmaceutical ingredients [23]. General 
methods used to encapsulate capsaicin are thin film hydration method, modified film method, 
film dispersion method [24]. Distinct advantages of using liposomes are high entrapment effi-
ciency, non-toxic, biodegradable, active ingredients encapsulated in liposomes are protected 
Figure 4. Lipid based carrier classification.
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Figure 5. A represents micelle and B represents dendrimer.
from immediate dilution or degradation. A microemulsion is defined as a system of water, oil, 
and amphiphile which is single optically isotropic and thermodynamically stable liquid solu-
tion [25]. Solid lipid nanoparticles are a new generation of colloidal drug carrier systems and 
consist of surfactant-stabilized lipids that are solid both at room and body temperatures [26].
5.1.1. Examples
Oral administration of Capsaicin Liposomes of mean size 52.2 ± 1.3 nm, had resulted in the 
encapsulation of Capsaicin with encapsulation efficiency 81.9 ± 2.43%, resulting in a 3.34-fold 
increase in bioavailability, as well the formulation reduces inflammation in gastric mucosa 
model [27]. Cather administration of phosphatidylcholine (PC) liposomes of the mean size 
smaller than 100 nm, were proven to benefit bladder irritation [28]. Oral administration of 
microemulsion consisting of Cremophor EL, ethanol, medium-chain triglycerides (oil phase) 
and water (external phase) of mean size 53.5 ± 1.6 nm with encapsulation efficiency 85.3 ± 1.1%, 
had resulted in the 2.64-fold increase in bioavailability, safe and effective [29]. Transdermal 
delivery of capsaicin, encapsulated in microemulsions based on non-ionic surfactants con-
sisting of isopropyl myristate as the oil phase, Comperlan® KD as the surfactant, ethanol as 
cosurfactant, and reverse osmosis water as aqueous phase resulted in use of low dose cap-
saicin [0.15% (w/w)] as effective delivery when compared to current clinical products [30]. 
Solid lipid nanoparticles were used to encapsulate capsaicin with mean size 100 nm, pro-
longed release of the drug is observed for a duration of 14 h, encapsulation efficiency found to 
be 90%, and further studies are needed to understand PK and PD studies [31].
5.2. Polymeric carriers
Micelles and dendrimers are chosen under the category of polymeric carriers (as shown in 
Figure 5).Briefly, micelles are defined as nanoscopic core/shell structures formed by amphi-
philic copolymers. These have a high potential to deliver compounds that are hydrophobic 
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and exhibit bioavailability. Dialysis method (organic-solvent free method) and solvent-switch 
method (direct dissolution method) are used for self-assembly of AB or ABA polymers into 
micelles in solutions. These are used primarily to incorporate water-soluble drugs. Direct dis-
solution and dialysis methods are used to synthesize polymeric micelles.
5.2.1. Examples
Oral administration of capsaicin with polyvinylpyrrolidone (PVP)/sodium cholate/phospho-
lipid mixed micellar system was synthesized with mean size below 50 nm, with the 2.42-fold 
increase in bioavailability, as well reduced irritation on gastric mucosa [32]. Oral delivery of 
capsaicin using methoxy poly(ethylene glycol)-poly(ε-caprolactone) (called as MPEG-PCl) 
nanoparticles of mean size 82.54 ± 0.51 nm, acquired sustained release for 60 h. Pharmacokinetics 
revealed 6-fold increase and reduced gastric mucosa irritation is observed [33].
5.3. Polymeric dendrimers
Dendrimers consists of tree-like branches with many functional terminals ends also con-
sidered as monodisperse macromolecules. These are prepared using convergent or diverge 
methods and growth is dependent on cascade regions.
5.3.1. Examples
The oleoyl chloride, Polyethylene glycol (PEG) 400, and triethylamine were used to synthesize 
dendrimers using esterification process and bound with capsaicin. The resulting formulation 
possesses mean size 143.1 nm and resulting formulation was found to be cytotoxic to MCF-7 
cells and Hep2 cells [34]and not toxic in case of zebrafish model [35].
5.4. Inorganic nanocarriers (metal nanoparticles, carbon spheres)
Inorganic nanocarriers are classified as metal nanoparticles and carbon spheres. Physical and 
chemical methods can be used to prepare metal nanoparticles, and they can exhibit multifunc-
tional properties, size-dependent metal to non-transition. Functionalized with groups like 
thiols are responsible for bioconjugate chemistry application, fluorescent particles [36]. Till 
date, few applications support the use of inorganic nanocarriers. Use of copper sulfide (CuS) 
nanoparticles, when functionalized with antibodies targeting TRPV1, the complex acted as a 
photothermal switch, and results were found to be significant and can be used in future as 
a therapeutic tool, to attenuate atherosclerosis [37]. Another application revealed that capsa-
icin as bioreductant of silver nitrate to form silver nanoparticles and the resulting capsaicin-
capped silver nanoparticles (mean size 20–30 nm) were found to be compatible with blood 
groups, and no further studies on this nanomaterial complex [38]. High sensitivity assay was 
developed when glass carbon electrodes are coated with carbon nanotubes, resulted in excel-
lent detection of capsaicin in various pepper samples [39]. Based on the literature, it is evident 
that use of metal nanoparticles and carbon nanotubes to improve the bioavailability, increase 
the half-life and improve pharmacokinetic (PK) and Pharmacodynamic (PD) of capsaicin, is 
the new area to be explored to enhance the efficacy of capsaicin therapeutic.




Strategies to use micro-nanotechnology tools to deliver capsaicin have exhibited tremen-
dous therapeutic potency for treating pain, cancer and other diseases at a research level. 
More studies are required at the basic and clinical stage to demonstrate their efficacy. The 
tools described in this study can also be used to deliver capsaicin through different routes 
of administration. Of course, potential challenges like delivery of the exact dose, maintain 
physicochemical properties of materials and capsaicin, the biodegradability of materials used 
to encapsulate capsaicin.
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